Oncogenic NRAS mutations have shown to regulate cancer cell proliferation, metastasis, and response to targeted therapies and chemotherapy by modulating several oncogenic signaling pathways such as MAPK pathway, PI3K-AKT signaling pathway among others [7, 8]. This evidence concerns the gene AKT1 and cancer.